Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy

The programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key molecules of immune checkpoint mechanisms in cancer and actually represent one of the main targets of immunotherapy. The predictive and prognostic values of PD-L1 expression alone in cancer patients is currently under debate due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabrizio, Federico Pio, Trombetta, Domenico, Rossi, Antonio, Sparaneo, Angelo, Castellana, Stefano, Muscarella, Lucia Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299305/
https://www.ncbi.nlm.nih.gov/pubmed/30574211
http://dx.doi.org/10.1177/1758835918815598
_version_ 1783381454202339328
author Fabrizio, Federico Pio
Trombetta, Domenico
Rossi, Antonio
Sparaneo, Angelo
Castellana, Stefano
Muscarella, Lucia Anna
author_facet Fabrizio, Federico Pio
Trombetta, Domenico
Rossi, Antonio
Sparaneo, Angelo
Castellana, Stefano
Muscarella, Lucia Anna
author_sort Fabrizio, Federico Pio
collection PubMed
description The programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key molecules of immune checkpoint mechanisms in cancer and actually represent one of the main targets of immunotherapy. The predictive and prognostic values of PD-L1 expression alone in cancer patients is currently under debate due to the methodological assessment of PD-L1 expression and its temporal variations. Better detailed studies about the molecular basis of immunotherapy biomarkers are necessary. Here we summarize the current knowledge of PD-L1 gene modifications at genetic and epigenetic levels in different tumors, thus highlighting their reported correlation with cellular processes and potential impact on patient outcomes.
format Online
Article
Text
id pubmed-6299305
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-62993052018-12-20 Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy Fabrizio, Federico Pio Trombetta, Domenico Rossi, Antonio Sparaneo, Angelo Castellana, Stefano Muscarella, Lucia Anna Ther Adv Med Oncol Review The programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key molecules of immune checkpoint mechanisms in cancer and actually represent one of the main targets of immunotherapy. The predictive and prognostic values of PD-L1 expression alone in cancer patients is currently under debate due to the methodological assessment of PD-L1 expression and its temporal variations. Better detailed studies about the molecular basis of immunotherapy biomarkers are necessary. Here we summarize the current knowledge of PD-L1 gene modifications at genetic and epigenetic levels in different tumors, thus highlighting their reported correlation with cellular processes and potential impact on patient outcomes. SAGE Publications 2018-12-17 /pmc/articles/PMC6299305/ /pubmed/30574211 http://dx.doi.org/10.1177/1758835918815598 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Fabrizio, Federico Pio
Trombetta, Domenico
Rossi, Antonio
Sparaneo, Angelo
Castellana, Stefano
Muscarella, Lucia Anna
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title_full Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title_fullStr Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title_full_unstemmed Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title_short Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
title_sort gene code cd274/pd-l1: from molecular basis toward cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299305/
https://www.ncbi.nlm.nih.gov/pubmed/30574211
http://dx.doi.org/10.1177/1758835918815598
work_keys_str_mv AT fabriziofedericopio genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy
AT trombettadomenico genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy
AT rossiantonio genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy
AT sparaneoangelo genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy
AT castellanastefano genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy
AT muscarellaluciaanna genecodecd274pdl1frommolecularbasistowardcancerimmunotherapy

Ejemplares similares